Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
Enrolling by invitation · Phase 2
Conditions studied: Pancreatic Cancer Non-resectable
In brief
This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer. The study will evaluate the efficacy and safety of nintedanib combined with radiotherapy and chemotherapy (gemcitabine or capecitabine monotherapy). The primary endpoint of this study is the 1-year local control rate (LCR).
Key facts
- Study ID
- NCT07386704
- Run by
- Peking University First Hospital
- People needed
- 30
- Starts
- 2025-12-09
- Expected to finish
- 2027-12-09
- Last updated by the study team
- 2026-02-04
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Confirmed by histological or cytological examination as pancreatic adenocarcinoma;
- Confirmed by imaging as locally advanced or oligometastatic (number of metastatic lesions ≤ 3);
- Evaluated by the clinical doctor as inoperable or the patient refuses surgery;
- ECOG PS score 0-1;
- No radiotherapy has been performed on the upper abdomen before, and no any palliative chemotherapy or other systemic anti-tumor treatment has been received;
- According to the RECIST 1.1 evaluation criteria, there are measurable lesions;
- Sufficient organ and bone marrow functions
You may not qualify if…
- Previous history of abdominal radiotherapy.
- Those with a history of other malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ).
- Those allergic to the drugs or their components used in this protocol.
- Those with known HIV or syphilis infection, or currently in the active stage of hepatitis (hepatitis B or hepatitis C).
- Those who have undergone major surgery within 30 days before screening.
- Those who have used EGFR monoclonal antibody or EGFR-TKI within 30 days before screening.
- Pregnant or lactating women.
- Those judged by the investigator to have other reasons unsuitable for participating in this study.
Where it is running
- Department of Radiotherapy Oncology, Peking University First Hospital — Beijing, Beijing Municipality, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.